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Methamphetamine (Meth) is a widely abused stimulant drug, but this abuse is associated 
with an increased risk of developing psychosis. In addition to its well-known action on 
brain dopamine, Meth also affects serotonergic (5-HT) neurons. The aim of this study 
was to investigate this role in mice, which lack one of the main serotonin receptors, the 
5-HT1A receptor, which has been implicated in both schizophrenia and Meth-induced 
psychosis. Male and female wild-type or 5-HT1A knockout (KO) mice received daily treat-
ment with increasing doses of methamphetamine from 6 to 9 weeks of age (1–4 mg/kg/
day twice a day). At least 2 weeks after the last injection, the mice underwent a battery 
of behavioral tests focusing on psychosis-related behaviors, including Meth-induced 
hyperactivity, prepulse inhibition (PPI), social interaction, elevated plus maze (EPM), 
and Y-maze. Meth pretreatment resulted in significantly increased hyperlocomotion in 
response to an acute Meth challenge, but this effect was independent of genotype. 
Chronic Meth treatment resulted in decreased levels of anxiety in the EPM in both sexes, 
as well as increased startle responses in female mice only, again independent of geno-
type. 5-HT1A KO mice showed an increased locomotor response to acute Meth in both 
sexes, as well as increased PPI and decreased startle responses in female mice only, 
independent of Meth pretreatment. In conclusion, the effects of chronic Meth appear 
unaffected by the absence of the 5-HT1A receptor. These results do not support a role of 
the 5-HT1A receptor in Meth-induced psychosis.
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inTrODUcTiOn
Methamphetamine (Meth) use and availability has been increasing worldwide and is placing a 
huge burden on users, their relatives and friends, and society at large (1). One of the most severe 
consequences of Meth abuse in some users is the development of psychosis (2, 3), either acutely when 
the drug is active or as long-term symptoms, which may be similar to schizophrenia (2–4). Users 
may also develop other persistent psychiatric symptoms or impaired cognitive abilities following 
TaBle 1 | number and mean weight of experimental groups.
group n Body weight (g) at end of testing
Males
WT-Saline 12 28.0 ± 0.7
WT-Meth 12 30.4 ± 0.6
5-HT1A KO-Saline 12 28.8 ± 0.7
5-HT1A KO-Meth 16 29.6 ± 0.5
Females
WT-Saline 12 22.4 ± 0.3
WT-Meth 13 22.3 ± 0.3
5-HT1A KO-Saline 16 22.5 ± 0.4
5-HT1A KO-Meth 11 23.4 ± 0.4
Genotype: 5-HT1A knockout (KO) or wild-type (WT).
Pretreatment: saline or methamphetamine (Meth).
Body weight: mean (±SEM).
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prolonged use of the drug (4, 5). However, the mechanisms 
involved in Meth psychosis, and its overlap with schizophrenia 
symptoms, remain unclear.
We have previously investigated the effects of chronic Meth on 
psychosis-like behavior in adulthood using a dosing schedule of 
escalating exposure during late adolescence/early adulthood. At 
least 2 weeks after the chronic treatment ended, the long-lasting 
effects of chronic Meth on a locomotor hyperactivity model 
of psychosis, as well as on cognition and other behaviors with 
relevance to psychiatric symptoms, were studied (6–8). Acute 
amphetamine- or Meth-induced locomotor hyperactivity is a 
widely used behavioral test in preclinical schizophrenia research, 
as it models the increase in dopamine signaling thought to 
contribute to psychosis (9). Sensitization of this dopaminergic 
signaling has been postulated to mimic developmental mecha-
nisms in psychosis (10, 11). In our experiments, pretreatment 
with Meth led to sensitization to the acute effects of amphetamine 
in the hyperactivity model compared to control pretreatment (6), 
while Meth pretreatment reduced the effect of an acute injection 
of amphetamine on prepulse inhibition (PPI) of acoustic startle 
(PPI) (7). Further studies showed that the chronic dosing proto-
col altered social novelty behavior but not short-term memory in 
the Y-maze (8).
There is increasing evidence for a role of serotonin, as well 
as dopaminergic mechanisms, in schizophrenia. Postmortem 
studies have shown increased expression of 5-HT1A receptors in 
the frontal cortex (12) but decreased binding in the amygdala in 
patients with schizophrenia (13). A polymorphism in the 5-HT1A 
receptor was associated with schizophrenia psychopathology (14) 
and several atypical antipsychotic drugs have high affinity for 
serotonergic receptors, including the 5-HT1A receptor (15–19). 
Extensive evidence suggests that 5-HT1A receptor activation 
modulates dopamine activity and may enhance cognition in 
schizophrenia (15, 17, 20, 21). While much of the animal litera-
ture has focused on the role of 5-HT1A in anxiety, where studies 
have shown 5-HT1A knockout (KO) mice to have a robust anxiety 
phenotype behavior in the elevated plus maze (EPM) (22–25) 
and certain fear conditioning paradigms (26), more recent work 
has investigated its role in schizophrenia-related behaviors. For 
example, 5-HT1A KO mice have an enhanced locomotor response 
to d-amphetamine compared to wild-type (WT) mice (27), an 
altered PPI response to methylenedioxymethamphetamine (28), 
and impaired cognition in the Morris Water maze (25, 29). The 
5-HT1A antagonist WAY100635 has also been shown to increase 
PPI in C57BL/6 mice (30).
These previous studies suggest a role for 5-HT1A receptors 
in schizophrenia although it is less clear if this extends to Meth 
psychosis. While several studies have suggested a role for 5-HT1A 
receptors in addiction to this drug (31), a role for this receptor 
in sensitization of Meth-induced hyperlocomotion is less clear 
(32). For example, the 5-HT1A receptor antagonist, WAY100635, 
had no effect on amphetamine or Meth-induced hyperlocomo-
tor activity (33, 34), while in contrast, the agonist, 8-OH-DPAT, 
was able to inhibit hyperlocomotion (33). 8-OH-DPAT and the 
5-HT1A receptor agonist, osemozotan, also prevented develop-
ment and expression of amphetamine or Meth-induced behav-
ioral sensitization (35, 36). However, the long-lasting effects of 
chronic Meth to induce psychosis-like behavior have not been 
studied in animals with genetically modified 5-HT1A receptor 
levels. The current study was, therefore, designed to investigate 
the effect of 5-HT1A receptor KO on the action of Meth to induce 
psychosis- and schizophrenia-related behaviors. We used the 
acute Meth-induced hyperactivity model of psychosis as well 
as a range of other relevant behavioral tests, including PPI for 
sensorimotor gating, social interaction as a model of some of the 
negative symptoms of schizophrenia, Y-maze and fear condition-
ing to assess cognitive changes, and EPM for anxiety. 5-HT1A KO 
mice or WT controls were tested during adulthood after a 3-week 
binge protocol of Meth administration during late adolescence. 
As previous studies have shown sex differences in animal models 
of psychosis (37) as well as the effect of this Meth dosing proto-
col on some behaviors (7, 8), both male and female mice were 
included in this study.
MaTerials anD MeThODs
animals
5-HT1A receptor KO mice and their C57BL/6 WT control lit-
termates (WT) (27) were derived from a breeding colony at the 
La Trobe Animal Research and Teaching Facility. Heterozygous 
mice were used as breeders to obtain WT and KO littermates 
for the current studies, while heterozygous offspring was not 
used. Genotypes were confirmed at weaning by Transnetyx Inc. 
(Cordova, TN, USA).
A total of 104 male and female mice were used for experiments 
(n = 10–16/group; Table 1). All mice were housed in groups of two 
to five during the experimental period in individually ventilated 
cages (Tecniplast, Buguggiate, Italy) with standard pellet food 
and water available ad libitum. Ambient temperature of housing 
and testing rooms was 21 ± 2°C and mice were housed under a 
12-h light–dark cycle, lights on at 0700 hours, with all behavioral 
testing conducted between 0800 and 1600 hours.
chronic Methamphetamine Treatment and 
experimental Procedure
Mice were given either Meth or saline as a vehicle control for 
five consecutive days a week for a period of 3  weeks during 
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adolescence, from the age of 6 to 9 weeks. Mice received 1 injec-
tion/day of 1  mg/kg during the first week, 2  injections/day of 
2 mg/kg the second week, and 2 injections/day of 4 mg/kg the 
third week (6–8). This protocol was based on a binge-type Meth 
intake pattern seen in many abusers of the drug, including occa-
sional interruptions of administration and a gradual increase of 
doses (38). The 2-week washout is required to be able to see the 
long-term effects of these chronic doses, which reflect increased 
effects in relapsed chronic users (38) as well as sensitization 
mechanisms similar to those postulated in psychosis develop-
ment (10, 11). Meth and saline solutions were given intraperi-
toneally at a volume of 5 ml/kg. Meth was purchased from the 
National Measurement Institute (Pymble, NSW, Australia) and 
dissolved in 0.9% sterile saline.
Starting 2 weeks following the final injection, at 11 weeks of 
age, mice underwent a battery of behavioral tests over a period of 
4 weeks, with less stressful tests performed first and more stress-
ful tests, or tests involving acute drug challenge, performed at 
the end. Mice were given at least 2–3 days between behavioral 
tests. Tests were performed in the following order: Y-maze, social 
interaction, EPM, fear conditioning, PPI, and Meth-induced 
locomotor hyperactivity.
Behavioral Testing
Methamphetamine-Induced Locomotor Hyperactivity
Mice were placed into automated photocell arenas (Med 
Associates, Fairfax, VT, USA), 27 cm × 27 cm with walls 40 cm 
high, with a 16 × 16 array of photobeam sensors for detecting 
movement. Each time, they were first habituated in the arenas 
for 1  h, then were removed briefly and injected with the chal-
lenge drug, then placed back into the arena for a further 2 h (6, 
27). During the first session, all mice received saline, followed 
by 1 mg/kg Meth in the second and 3 mg/kg Meth in the final 
session, with 3–4  days washout in between sessions. Distance 
traveled was automatically calculated in 5-min time bins.
PPI of Acoustic Startle
Prepulse inhibition was assessed as a measure of sensorimotor 
gating using automated SR-Lab startle chambers (San Diego 
Instruments, San Diego, CA, USA). Mice were placed in indi-
vidual plexiglass cylinders (5 cm diameter) and the test session 
consisted of 104 stimulus trials as previously described (7, 27). 
PPI was quantified as the difference between stimulus responses 
during prepulse-pulse and pulse-alone trials and expressed as a 
percentage of pulse-alone responses. At 30 ms ISI, mice showed 
no effect of genotype or pretreatment, therefore, results analysis 
will focus on the 100 ms ISI.
Social Interaction
The test apparatus consists of a rectangular three chambered 
enclosure, 43 cm × 64 cm, with transparent walls 23 cm high. Two 
“stranger” enclosures, diameter 9 cm, height 10 cm, were placed 
in the two outer chambers. The test consisted of three phases, 
each 10  min in duration, which were conducted immediately 
after one another (8, 39). Stranger mice were adolescent 5-HT1A 
heterozygous mice of the same sex as the test mouse. Interaction 
time was measured using Ethovision video tracking (Noldus, 
Wageningen, The Netherlands), with time spent in a “sniffing 
zone,” 2.5 cm immediately surrounding stranger cages, defined 
as interaction.
Elevated Plus Maze
The EPM consisted of an elevated plus-shaped platform with 
two open and two closed arms, with a length of 40 cm and width 
of 5 cm, 50 cm above the ground, with a central square section 
between arms (40, 41). During the 5-min trial, time spent in open 
and closed arms and number of entries into arms were measured 
using Ethovision video tracking (Noldus). Mice that spend more 
time in the open arms are considered to have a lesser anxiety 
phenotype. The total number of arm entries was used as a control 
measure of locomotor activity.
Y-Maze
The Y-maze was a Y-shaped apparatus with three arms (start 
arm and two test arms), each 32 cm long and 10 cm wide with 
walls 15 cm high. The arms were at a 120° angle from each other. 
The test arms had different black and white symbols on either 
end wall. Behavior was tracked using Ethovision (Noldus), 
which measured time spent in, and number of entries to, each 
arm (42, 43). Sessions included a 10-min trial with access to 
only two arms followed 1 h later but a 5 min re-trial with access 
to all three arms. Time spent in the novel test arm compared 
to the other arms (familiar and start) during the retention 
phase was used as a measure of short-term spatial recognition 
memory.
Fear Conditioning
Fear memory was assessed using a 3-day fear conditioning 
protocol as previously used in mice (43, 44) using chambers 
equipped with footshock grid floors (Med Associates). Two 
different conditioning contexts were used, which differed in lux, 
scent, bedding, and structure due to a concave wall insert, and 
mice were pseudorandomly assigned to one context or the other. 
Freezing was defined as complete lack of any movement besides 
breathing and was measured in response to (1) the context 
where mice had previously been exposed to an unconditioned 
stimulus (scrambled foot-shocks of 1 s duration, 0.7 mA) or (2) a 
conditioned stimulus (30 s duration, 7,500 Hz, 70 dB) previously 
presented prior to the US, but in a new context.
statistical analysis
Data were expressed as the mean ± SEM and differences between 
groups were analyzed with analysis of variance (ANOVA), with 
repeated measures where appropriate, using IBM SPSS Statistics 
23 (Armonk, New York, NY, USA). All data were first analyzed 
with genotype, Meth pretreatment and sex as between-group 
statistical factors. If significant interactions were seen, data were 
split and further analyzed by genotype, pretreatment, or sex as 
stated in the results. For locomotor activity analysis, repeated-
measures factors were time and acute Meth treatment, while 
for social interaction and Y-maze analysis, repeated measures 
factors were stranger mouse interaction time and time spent in 
arms, respectively. Differences between groups were considered 
significant when p < 0.05.
FigUre 1 | acute methamphetamine (Meth) induced hyperactivity following chronic Meth exposure. A low acute challenge dose of Meth (1 mg/kg) 
induced hyperactivity in mice previously pretreated with Meth. There was no genotype effect at this dose. A high acute challenge dose of Meth (3 mg/kg) induced 
hyperactivity to a significantly greater extent in Meth pretreated compared to saline pretreated mice. This dose also induced hyperactivity to a significantly greater 
extent in 5-HT1A knockout (KO) mice compared to wild-type (WT) mice. Results are shown for males and females combined.
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resUlTs
locomotor activity
Analysis of locomotor activity following 1 and 3  mg/kg Meth 
compared to saline control showed a significant main effect of 
an acute Meth challenge [F(2, 188) = 273, p < 0.001] and a treat-
ment × pretreatment interaction [F(2, 188) = 73.3, p < 0.001]. Data 
were, therefore, split and further ANOVAs were used to compare 
the effect of each dose of acute Meth with saline to further explore 
this relationship. Although females showed higher activity than 
males [F(1, 94) = 16.4, p < 0.001], there were no significant interac-
tions between sex and genotype, acute treatment or pretreatment, 
therefore, locomotor activity results for males and females were 
combined (Figure 1).
Following acute injection with 3  mg/kg Meth, all groups 
showed a significant main effect of treatment compared to 
saline injection [F(1, 94) = 307, p < 0.001]. This effect was much 
greater in Meth-pretreated mice [treatment  ×  pretreatment 
F(1, 94) =  87.3, p <  0.001], indicating sensitization to a chal-
lenge dose of Meth following the binge dosing protocol used, 
and was also greater in 5-HT1A KO mice than in WT controls 
[treatment ×  genotype F(1, 94) =  5.10, p =  0.026]. There was, 
however, no treatment × pretreatment × genotype interaction, 
suggesting the genotype differences and Meth sensitization 
were independent of each other.
Acute injection with 1 mg/kg Meth showed similar results 
[treatment F(1, 94) = 24.9, p < 0.001; treatment × pretreatment 
F(1, 94) =  18.0, p <  0.001]; however, the effect of genotype in 
response to acute Meth failed to reach significance at this dose.
Prepulse inhibition
Analysis of PPI at 100 ms ISI showed a significant genotype × sex 
interaction [F(1, 104) = 5.77, p = 0.018]; therefore, data were fur-
ther analyzed separately for male and female mice (Figure 2A). 
Female, but not male, 5-HT1A KO mice showed significantly 
higher PPI than WT mice [main effect of genotype F(1, 54) = 9.08, 
p = 0.004]. However, there was no effect of Meth pretreatment on 
PPI in any of the groups.
Analysis of startle response showed that male mice had 
significantly higher startle compared to females [F(1, 104) = 15.1, 
p < 0.001] while there was also a significant main effect of geno-
type [F(1, 104) = 4.43, p = 0.038] and a genotype × sex interaction 
[F(1, 104) =  4.52, p =  0.036] suggesting a genotype effect, which 
was dependent on sex (Figure 2B). We, therefore, again further 
analyzed results separately for male and female mice. As with 
PPI, male mice showed no difference between groups, while in 
females, 5-HT1A KO mice showed significantly lower startle than 
WT mice [main effect of genotype F(1, 54) = 17.6, p < 0.001]. It was 
also shown that female Meth pretreated mice had significantly 
higher startle compared to controls [main effect of pretreatment 
F(1, 54) = 4.08, p = 0.048]; however, there was no genotype × pre-
treatment effect, suggesting that these results were independent 
of each other.
social interaction
Analysis of total time spent interacting with the stranger mouse 
and empty cage showed a significant preference for the stranger 
mouse [F(1, 78) = 150, p < 0.001], but there was no statistical inter-
action with genotype, pretreatment, or sex, indicating all groups 
showed similar sociability (Figure 3A).
In contrast, while analysis of the total time spent interacting 
with the familiar and novel stranger mice again showed a signifi-
cant preference for the novel stranger [F(1, 78) = 51.6, p < 0.001] 
and no statistical interaction with genotype or pretreatment, 
there was a significant interaction between stranger time and sex 
[F(1, 78) = 5.6, p = 0.021; Figure 3B]. This suggests that there were 
no effects of genotype or Meth pretreatment on social novelty 
behavior, but that female mice show a decreased preference for 
the novel over the familiar stranger mouse.
elevated Plus Maze
Analysis of time spent in the open arms of the EPM showed 
a significant main effect of Meth pretreatment [F(1, 94) =  8.17, 
p =  0.005] reflecting that this pretreatment leads to increased 
time spent on the open arms of the EPM, suggesting decreased 
anxiety in these mice (Figure 4A). There was no significant main 
effect of genotype or sex; therefore, results have been presented 
for both sexes combined.
Total number of arm entries was analyzed as an indicator 
of activity on the plus maze (WT-Saline 42.2 ± 4.2, KO-Saline 
FigUre 2 | (a) Average prepulse inhibition (PPI) across all four PP intensities was significantly higher in 5-HT1A knockout (KO) females compared to wild-type (WT) 
females. There was no difference in PPI between any groups in male mice. (B) Average startle responses across all four startle blocks were significantly lower in 
female 5-HT1A KO mice compared to WT, and higher in female Meth pretreated compared to saline pretreated mice. There was no difference in startle between any 
groups in male mice. ** signifies genotype effect p < 0.01, *** signifies p < 0.001.
5
Jaehne et al. 5-HT1A Receptor in Methamphetamine Psychosis
Frontiers in Psychiatry | www.frontiersin.org April 2017 | Volume 8 | Article 61
45.1 ± 3.6, WT-Meth 46.5 ± 4.3, KO-Meth 47.0 ± 3.8). The results 
showed that there were no differences in activity between groups; 
therefore, overall activity did not have any effect on the different 
anxiety levels seen.
Y-Maze
Analysis of total time spent in each arm of the Y-maze showed 
a significant main effect of arms [F(2, 184) =  91.6, p <  0.001], 
but no significant interaction of time in arms with genotype, 
pretreatment, or sex indicating all groups showed a similar 
preference for the novel arm and have intact short-term spatial 
memory (Figure  4B). There was no significant main effect 
of sex; therefore, results have been presented for both sexes 
combined.
Fear conditioning
Analysis of context freezing (WT-Saline 42.3 ± 4.3, KO-Saline 
45.6 ±  3.4, WT-Meth 44.7 ±  3.6, KO-Meth 40.9 ±  3.5%) and 
tone freezing (WT-Saline 43.5  ±  4.9, KO-Saline 55.5  ±  4.3, 
WT-Meth 49.0 ± 4.9, KO-Meth 48.1 ± 4.1) showed that there 
were no differences between the groups, suggesting that neither 
Meth pretreatment nor 5-HT1A genotype have any effect on fear 
memory.
DiscUssiOn
This study showed that, while both the Meth binge dosing and 
5-HT1A receptor KO genotype alter behavior in mice, 5-HT1A 
KO mice did not respond differently to chronic Meth pretreat-
ment in any of the behaviors tested. Meth pretreatment resulted 
in a heightened response to acute Meth and decreased levels of 
anxiety in both sexes, as well as increased startle responses in 
female mice only, independent of genotype. However, 5-HT1A KO 
mice also showed an increased response to acute Meth in both 
sexes, as well as increased PPI and decreased startle response in 
female mice only, independent of Meth pretreatment. There were 
no effects on either short-term spatial memory in the Y-maze 
or conditioned fear memory induced by either Meth or 5-HT1A 
receptor KO genotype.
These studies were first able to confirm that chronic escalat-
ing Meth exposure during adolescence/young adulthood leads 
to sensitization to the effects of an acute challenge dose of Meth 
in adulthood, consistent with previous studies (6). We were also 
able to confirm that 5-HT1A KO mice have a greater response 
to acute Meth compared to WT consistent with their enhanced 
sensitivity seen following acute d-amphetamine previously 
(27). However, there was no statistical interaction between the 
FigUre 3 | social behavior in the three-chamber task. (a) Sociability, as measured by preference to interact with a stranger mouse compared to an empty 
cage, was normal in all groups (indicated by * above stranger). (B) Social novelty preference, as measured by preference to interact with novel stranger mouse, was 
also normal in all groups (indicated by * above stranger), although female mice showed a lower preference compared to males. *p < 0.05.
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two effects, as reflected by the observation that KO mice did 
not show an altered sensitivity to acute re-exposure to a single 
challenge dose of Meth compared to WT mice. These results 
suggest that the 5-HT1A receptor is likely important in the acute 
action of Meth to induce hyperactivity but is not required for the 
development of sensitization induced by prior binge dosing of 
Meth. A previous study in the laboratory showed that the bind-
ing density of the dopamine transporter (DAT) and dopamine 
receptors D1 and D2 is only changed subtly in 5-HT1A KO mice 
(27) and suggested that the interaction of 5-HT1A receptors with 
dopamine release is at a more immediate functional level (45) 
rather that via more long-term changes in the expression of DAT 
or dopamine receptors.
Male mice showed no effect of genotype or Meth pretreat-
ment on either PPI or startle response. Female 5-HT1A KO mice, 
however, showed increased PPI and decreased startle responses 
compared to WT. The results are partly consistent with a pre-
vious study, which showed that administration of the 5-HT1A 
antagonist, WAY100635, led to an increase in PPI in C57BL/6 
mice (30); however, this was only done in male mice, which 
showed no changes in PPI between genotypes in the current 
study. While Meth pretreatment did not alter PPI in either sex, 
there was also a small but significant effect of Meth pretreat-
ment to increase startle response in female mice; however, the 
effects of genotype and pretreatment were again independent 
of each other. Therefore, as with locomotor hyperactivity, Meth 
pretreatment had no specific effect in 5-HT1A KO mice only. This 
is similar to previous studies using Meth pretreatment where 
no differences were seen in baseline PPI in either sex following 
binge Meth dosing (7).
There were no effects of Meth pretreatment or 5-HT1A geno-
type on social behavior using the three-chamber sociability and 
social novelty preference tests. A previous study in the lab showed 
the same results for sociability, although suggested that Meth pre-
treatment decreased preference for social novelty to a lower level 
than saline pretreated mice in males only (8), while other studies 
have also shown impaired social behavior in animals previously 
exposed to Meth (46, 47).
5-HT1A KO mice showed no signs of increased or decreased 
anxiety in the EPM, which is in contrast to other studies con-
ducted in these mice, which have shown an anxious phenotype 
on the EPM and other tests of anxiety (22–26). Differences in 
experimental conditions such as conducting other behavioral 
tests prior to the elevated zero maze could contribute to the 
differences seen here compared to previous studies. Future stud-
ies should test for an anxiety phenotype in these mice prior to 
further behavioral testing to confirm presence of the phenotype. 
Importantly, however, Meth pretreatment led to increased time 
spent in the open arms of the plus maze, suggesting that these 
mice were less anxious than controls, but this effect was again 
FigUre 4 | (a) Time spent in the open arms of the elevated plus maze was 
higher in Meth pretreated mice compared to saline pretreated. (B) Short-term 
spatial memory, measured by preference to spend time in the novel arm of 
the Y-maze, was normal in all groups (indicated by * above novel arm). 
*p < 0.05, **p < 0.01. Results are shown for males and females combined.
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independent of genotype. Previously, effects of chronic Meth 
pretreatment on anxiety have been variable. For example, a 
10-day escalating dose protocol in mice induced no changes 
in anxiety measures in the EPM or light/dark box (48) while 
studies in rats showed increased anxiety or no change in the 
EPM depending on the age or extent of Meth exposure or time 
following exposure (49–51). These results suggest that dosing 
and testing protocol are very important for long-term effects of 
Meth on behavior.
A limitation of using 5-HT1A KO mice is that the absence 
of these receptors during embryogenesis and development 
may influence the role of these receptors on behavior and 
the development of Meth sensitization. For example, changes 
in receptor density or function may change over time, and 
this could be altered by absence of the receptors during 
early development. Future studies could use conditional KO 
mice in which the receptor is deleted only in adulthood. 
Any differential role of presynaptic and postsynaptic 5-HT1A 
receptors, which would both be absent in our KO mice, is also 
not addressed in this study. Previous research using 5-HT1A 
agonists suggest that, while antagonists have no effect on 
behavioral sensitization (33, 34), the effects of the agonists 
may have been due to the activation of the presynaptic 
receptors preferentially over postsynaptic receptors (52). 
Studies show that both 8-OH-DPAT and osemozotan are able 
to prevent the development and expression of amphetamine or 
Meth-induced behavioral sensitization (35, 36), these effects 
were also reversed by the antagonist WAY100635, which has 
a greater affinity for presynaptic 5-HT1A autoreceptors (53). 
Other limitations of this study are that the estrus cycle of 
female mice was not monitored, which could strengthen the 
results of any study using female animals, and the fact that we 
did not see an anxiety phenotype in the 5-HT1A KO mice as 
discussed above.
While this study showed that there was no interaction 
between Meth pretreatment and the 5-HT1A receptor in the 
protocols used, there is evidence that other 5-HT receptors 
may be involved in the long-term effects of Meth and Meth-
induced sensitization. Repeated Meth administration failed 
to induce behavioral sensitization in 5-HT reuptake KO mice, 
but this was rescued by administration of a 5-HT1B antagonist 
(54). Many different 5-HT receptor agonists and antagonists 
have been investigated for their role in behavioral sensitization 
induced by Meth. For example, the 5-HT1B receptor antago-
nist, SB 216641, inhibited development but not expression 
of amphetamine-induced sensitization (55) while the 5-HT2 
receptor antagonist, ritanserin, inhibited the development, 
expression, and maintenance of Meth-induced behavioral 
sensitization (56, 57). Taken together, the current findings in 
5-HT1A receptor KO mice do not support a role of these recep-
tors in Meth-induced psychosis, although this does not rule out 
a role of other serotonin receptors, which can be addressed in 
future studies with selected KO lines such as 5-HT1B and 5-HT2 
receptor KO mice.
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